Top Page
Prophase Labs
(OTC:PRPH)
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Prophase Labs Business Overview & Revenue Model
Prophase Labs Earnings Call Summary
Prophase Labs Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08M | 6.77M | 44.38M | 122.65M | 79.04M | 14.51M |
| Gross Profit | 2.06M | -150.00K | 16.24M | 70.65M | 32.81M | 4.61M |
| EBITDA | -24.81M | -32.34M | -14.83M | 28.73M | 11.39M | -1.49M |
| Net Income | -41.70M | -53.36M | -16.78M | 18.46M | 6.27M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 65.70M | 63.20M | 91.93M | 87.65M | 89.30M | 31.41M |
| Cash, Cash Equivalents and Short-Term Investments | 405.00K | 678.00K | 4.74M | 17.44M | 17.51M | 8.46M |
| Total Debt | 7.68M | 24.57M | 18.46M | 6.96M | 14.90M | 14.72M |
| Total Liabilities | 58.84M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M |
| Stockholders Equity | 6.86M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M |
Cash Flow | ||||||
| Free Cash Flow | -22.75M | -18.44M | -14.50M | 24.63M | -17.85M | -4.28M |
| Operating Cash Flow | -22.99M | -17.54M | -11.35M | 28.55M | -13.62M | -2.59M |
| Investing Cash Flow | -40.00K | 2.42M | -1.37M | -2.08M | -19.67M | -1.02M |
| Financing Cash Flow | 9.66M | 14.19M | 5.76M | -26.02M | 35.13M | 9.99M |
Prophase Labs Technical Analysis
Prophase Labs Risk Analysis
Prophase Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $26.49M | -0.85 | -50.23% | ― | -15.61% | -68.96% | |
52 Neutral | $25.00M | 82.76 | 0.27% | ― | 75.19% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $27.69M | -0.35 | -37.38% | ― | -22.60% | 53.82% | |
49 Neutral | $10.92M | -0.27 | -44.42% | ― | -1.50% | 80.17% | |
42 Neutral | $1.47M | -0.01 | ― | ― | ― | ― | |
40 Underperform | $6.82M | -1.65 | -93.87% | ― | -0.74% | 81.49% |
Prophase Labs Corporate Events
On January 26, 2026, ProPhase Labs, Inc. announced it had issued an operational update on the progress of its Crown Medical Collections initiative, which concerns legacy COVID-19 testing receivables tied to its laboratory subsidiaries that are currently in Chapter 11 proceedings. The update underscores the company’s ongoing efforts to address and manage outstanding pandemic-era testing receivables in the context of its subsidiaries’ bankruptcy process, an issue of material importance to its security holders given the potential impact on recoveries and financial positioning.
The most recent analyst rating on (PRPH) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On January 16, 2026, ProPhase Labs, Inc. entered into a Stock Purchase Agreement with Generating Alpha Ltd., securing access to up to $10 million in equity capital through an at‑the‑company’s‑discretion equity line facility. Under the deal, ProPhase granted the investor 549,105 shares of common stock and a prefunded warrant for up to 240,369 additional shares as a commitment fee, with any further share issuance occurring only at the company’s election, providing flexible, non-obligatory funding that may strengthen its balance sheet and financial optionality without imposing mandatory capital raises on existing stakeholders.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On January 22, 2026, ProPhase Labs, Inc. announced that its common stock had been approved for uplisting from the Pink Sheets to the OTCID Market. The move marks a significant step in enhancing the company’s trading venue, which may improve visibility and liquidity for its shares and is likely to be viewed as a positive development by existing and prospective shareholders.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On January 5, 2026, Prophase Labs issued an update to shareholders explaining that recent volatility in its common stock was largely driven by technical factors tied to its capital structure, including an accelerated conversion and resale of most of its outstanding convertible debt, a 1-for-10 reverse stock split completed on December 5, 2025, and the company’s move from the Nasdaq Capital Market to trading on the OTC market as of January 5, 2026, following its delisting from Nasdaq. The company reported that more than $3.3 million of an initial $3.8 million in convertible debt principal had been converted into equity, leaving less than $500,000 unconverted, and noted that these conversions, executed at a floor price well above the recent market price, increased the share count but reduced indebtedness dollar-for-dollar and strengthened the balance sheet, even as the influx of new shares contributed to short-term selling pressure and potentially reduced liquidity and institutional interest; management stressed that it views the intrinsic value of its subsidiaries and assets, as well as its long-term strategy and growth prospects, as unchanged by these mechanics and is focused on stabilizing its capital structure, completing near-term financing initiatives, and advancing its core operations, while cautioning that the stock may remain volatile.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.24 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On January 5, 2026, ProPhase Labs, Inc. announced that board member Warren Hirsch resigned from the company’s Board of Directors, effective immediately. The company stated that his departure was not due to any disagreement over operations, policies, or practices, and publicly expressed appreciation for his service and contributions during his tenure, suggesting an orderly and non-contentious transition at the board level.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.24 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On December 29, 2025, ProPhase Labs, Inc. disclosed that it had failed to regain compliance with Nasdaq’s $1.00 minimum bid price requirement by the end of its second 180-day grace period on December 22, 2025, triggering a determination by Nasdaq staff to delist the company from the Nasdaq Capital Market. Nasdaq has notified ProPhase that trading in its common stock is scheduled to be suspended at the opening of business on January 5, 2026, after which a delisting filing will be made with the U.S. securities regulator; in response, the company plans to appeal the decision to a Nasdaq Hearings Panel and is simultaneously seeking to have its shares quoted on the OTC Markets, a move that could affect liquidity and visibility for shareholders while leaving the company’s longer-term listing status uncertain.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.44 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological Laboratories S.A., a European biotechnology company, under which ABL would become the majority owner of the combined entity. The contemplated transaction, if completed, would significantly reshape ProPhase’s ownership structure and strategic direction by aligning it more closely with ABL’s biotech focus, with potential implications for shareholders and the company’s positioning in the broader healthcare and diagnostics market.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On November 30, 2025, Prophase Labs‘ stockholders approved a reverse stock split of its common stock at a ratio of one share for every ten shares, effective December 2, 2025. This move was aimed at increasing the per-share trading price to meet NASDAQ’s continued listing requirements. The reverse stock split did not alter stockholders’ percentage ownership, except for cash adjustments for fractional shares, and the company’s common stock continues to trade under the symbol ‘PRPH’.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On November 24, 2025, ProPhase Labs, Inc. conducted a Special Meeting of Stockholders where six proposals were presented and approved. The proposals included acquiring digital assets, creating a new class of digital treasury shares, issuing digital tokens, and authorizing stock splits. Proposal 4, concerning stock splits, notably met the approval requirements for charter amendments under Delaware law, indicating strong shareholder support and potential strategic shifts for the company.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On November 21, 2025, ProPhase Labs, Inc. received confirmation from Avtech Capital, LLC to continue its forbearance under an existing equipment lease, with a new payment schedule starting November 28, 2025. This arrangement ensures the company can bring its lease current without affecting its operations, liquidity, or financial reporting, as confirmed by their recent Form 10-Q.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On November 21, 2025, ProPhase Labs, Inc. disclosed that a civil action filed against it in 2023 had been unsealed by court order on November 4, 2025. The unsealing is a procedural step under the False Claims Act, and the company was unaware of the action until November 19, 2025. ProPhase Labs has not been served with the complaint and has received no indication of governmental intervention. The company denies any wrongdoing, maintains its compliance standards, and intends to defend itself vigorously. It also notes that a separate private dispute with Dr. Hennrick was resolved in April 2024. The company does not expect the unsealed matter to impact its operations.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On November 19, 2025, ProPhase Labs announced its strategic initiatives, including M&A discussions and the commercialization of the BE-Smart™ Esophageal Cancer Test following a landmark study. The company is also pursuing a $50 million collection initiative through Crown Medical, which has been appointed as Special Counsel to expedite litigation against insurance carriers. These efforts aim to unlock significant value for ProPhase, which it believes is not reflected in its current share price.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.